6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013 · The Lancet Oncology · 337 citations
https://doi.org/10.1016/s1470-2045(13)70225-0
P
P. Fumoleau
Institut Curie(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
489
Papers
21.4K
Citations
72
h-index
218
i10-index
P. Fumoleau is an academic researcher from Institut Curie. The author has contributed to research in topics: Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 72, co-authored 416 publications.
ORCID: 0000-0002-2912-2170Papers by this author
worksResults of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004 · JNCI Journal of the National Cancer Institute · 271 citations
https://doi.org/10.1093/jnci/djh133
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2012 · Journal of Clinical Oncology · 245 citations
https://doi.org/10.1200/jco.2011.37.4207
<i>In situ</i> immune response after neoadjuvant chemotherapy for breast cancer predicts survival
2011 · The Journal of Pathology · 223 citations
https://doi.org/10.1002/path.2866
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
2016 · Nature Communications · 157 citations
https://doi.org/10.1038/ncomms12222
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
2012 · The Lancet Oncology · 131 citations
https://doi.org/10.1016/s1470-2045(12)70508-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat